Trial Outcomes & Findings for A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants (NCT NCT01933880)

NCT ID: NCT01933880

Last Updated: 2014-09-17

Results Overview

The digit span test is mainly used to measure the ability of short-term memory and attention. The participant will be given a string of digits and asked to repeat them forward, and then a second string of digits to repeat backward. The score is the number of correct responses, where the digits were repeated correctly. One point will be given for each correctly repeated string of digits. The maximum subscore in the Digits Forward is 16, and the maximum subscore in the Digits Backward is 14, summed for a total score of 30. A higher score is indicative of better recall and attention.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

194 participants

Primary outcome timeframe

Baseline and Week 12

Results posted on

2014-09-17

Participant Flow

Participant milestones

Participant milestones
Measure
OROS-MPH Group
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
Overall Study
STARTED
153
41
Overall Study
COMPLETED
123
40
Overall Study
NOT COMPLETED
30
1

Reasons for withdrawal

Reasons for withdrawal
Measure
OROS-MPH Group
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
Overall Study
Withdrawal by Subject
5
0
Overall Study
Lack of Efficacy
1
0
Overall Study
Concomitant medication Interference
0
1
Overall Study
Followup exceeded 4 days to visit window
19
0
Overall Study
Other
4
0
Overall Study
Protocol Violation
1
0

Baseline Characteristics

A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
OROS-MPH Group
n=128 Participants
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
n=40 Participants
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
Total
n=168 Participants
Total of all reporting groups
Age, Customized
Less than 7 to 8 Years
48 participants
1.47 • n=99 Participants
10 participants
1.72 • n=107 Participants
58 participants
n=206 Participants
Age, Customized
9 to 10 Years
55 participants
n=99 Participants
16 participants
n=107 Participants
71 participants
n=206 Participants
Age, Customized
11 to 12 Years
25 participants
n=99 Participants
14 participants
n=107 Participants
39 participants
n=206 Participants
Sex: Female, Male
Female
20 Participants
n=99 Participants
17 Participants
n=107 Participants
37 Participants
n=206 Participants
Sex: Female, Male
Male
108 Participants
n=99 Participants
23 Participants
n=107 Participants
131 Participants
n=206 Participants

PRIMARY outcome

Timeframe: Baseline and Week 12

Population: Full Analysis Set (FAS) population for OROS-MPH Group included all participants who received at least one study drug therapy and had at least one efficacy evaluation. FAS for normal group included all participants who received baseline assessment scale evaluation and had at least one endpoint assessment scale evaluation.

The digit span test is mainly used to measure the ability of short-term memory and attention. The participant will be given a string of digits and asked to repeat them forward, and then a second string of digits to repeat backward. The score is the number of correct responses, where the digits were repeated correctly. One point will be given for each correctly repeated string of digits. The maximum subscore in the Digits Forward is 16, and the maximum subscore in the Digits Backward is 14, summed for a total score of 30. A higher score is indicative of better recall and attention.

Outcome measures

Outcome measures
Measure
OROS-MPH Group
n=128 Participants
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
n=40 Participants
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
OROS-MPH Group 54 mg
Participants with ADHD received OROS -MPH tablets orally daily at a dose of 56 milligram per day (mg/d)
Change From Baseline in Digit Span Test Total Score at Week 12
Baseline
11.7 Scores on a scale
Standard Deviation 2.25
13.7 Scores on a scale
Standard Deviation 2.43
Change From Baseline in Digit Span Test Total Score at Week 12
Change at Week 12
1 Scores on a scale
Standard Deviation 1.5
0.5 Scores on a scale
Standard Deviation 1.48

PRIMARY outcome

Timeframe: Baseline and Week 1

Population: FAS population for OROS-MPH Group. Here "N" signifies number of participants who were evaluable for this outcome measure. Data for Normal group was not analyzed for IOWA Conners scale since as per the planned analysis normal participants were only analyzed for the memory effect in cognitive function test.

IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening.

Outcome measures

Outcome measures
Measure
OROS-MPH Group
n=127 Participants
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
OROS-MPH Group 54 mg
Participants with ADHD received OROS -MPH tablets orally daily at a dose of 56 milligram per day (mg/d)
Change From Baseline in Inattention/Overactivity With Aggression (IOWA) Conners Behavior Rating Scale - I/O Score at Week 1
Baseline
10 Scores on a scale
Standard Deviation 2.4
Change From Baseline in Inattention/Overactivity With Aggression (IOWA) Conners Behavior Rating Scale - I/O Score at Week 1
Change at Week 1
-2.7 Scores on a scale
Standard Deviation 2.18

PRIMARY outcome

Timeframe: Baseline and Week 2

Population: FAS population for OROS-MPH Group. Here "N" signifies number of participants who were evaluable for this outcome measure. Data for Normal group was not analyzed for IOWA Conners scale since as per the planned analysis normal participants were only analyzed for the memory effect in cognitive function test.

IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening.

Outcome measures

Outcome measures
Measure
OROS-MPH Group
n=127 Participants
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
OROS-MPH Group 54 mg
Participants with ADHD received OROS -MPH tablets orally daily at a dose of 56 milligram per day (mg/d)
Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 2
Baseline
10 Scores on a scale
Standard Deviation 2.4
Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 2
Change at Week 2
-4.1 Scores on a scale
Standard Deviation 2.73

PRIMARY outcome

Timeframe: Baseline and Week 3

Population: FAS population for OROS-MPH Group. Here "N" signifies number of participants who were evaluable for this outcome measure. Data for Normal group was not analyzed for IOWA Conners scale since as per the planned analysis normal participants were only analyzed for the memory effect in cognitive function test.

IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening.

Outcome measures

Outcome measures
Measure
OROS-MPH Group
n=127 Participants
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
OROS-MPH Group 54 mg
Participants with ADHD received OROS -MPH tablets orally daily at a dose of 56 milligram per day (mg/d)
Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 3
Baseline
10 Scores on a scale
Standard Deviation 2.4
Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 3
Change at Week 3
-5 Scores on a scale
Standard Deviation 2.81

PRIMARY outcome

Timeframe: Baseline and Week 7

Population: FAS population for OROS-MPH Group. Here "N" signifies number of participants who were evaluable for this outcome measure. Data for Normal group was not analyzed for IOWA Conners scale since as per the planned analysis normal participants were only analyzed for the memory effect in cognitive function test.

IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening.

Outcome measures

Outcome measures
Measure
OROS-MPH Group
n=127 Participants
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
OROS-MPH Group 54 mg
Participants with ADHD received OROS -MPH tablets orally daily at a dose of 56 milligram per day (mg/d)
Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 7
Change at Week 7
-5.8 Scores on a scale
Standard Deviation 2.91
Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 7
Baseline
10 Scores on a scale
Standard Deviation 2.4

PRIMARY outcome

Timeframe: Baseline and Week 12

Population: FAS population for OROS-MPH Group. Here "N" signifies number of participants who were evaluable for this outcome measure. Data for Normal group was not analyzed for IOWA Conners scale since as per the planned analysis normal participants were only analyzed for the memory effect in cognitive function test.

IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening.

Outcome measures

Outcome measures
Measure
OROS-MPH Group
n=127 Participants
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
OROS-MPH Group 54 mg
Participants with ADHD received OROS -MPH tablets orally daily at a dose of 56 milligram per day (mg/d)
Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 12
Baseline
10 Scores on a scale
Standard Deviation 2.4
Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 12
Change at Week 12
-6.2 Scores on a scale
Standard Deviation 3.08

SECONDARY outcome

Timeframe: End of Week 1, 2, 3, 7 and 12

Population: FAS population for OROS-MPH Group included all participants who received at least one study drug therapy and had at least one efficacy evaluation. Data for Normal group was not analyzed for IOWA Conners scale since as per the planned analysis normal participants were only analyzed for the memory effect in cognitive function test.

Remission rate is the percentage of participants with total score of IO sub-scale less than or equal to 5 in IOWA Conners measurement scale

Outcome measures

Outcome measures
Measure
OROS-MPH Group
n=128 Participants
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
OROS-MPH Group 54 mg
Participants with ADHD received OROS -MPH tablets orally daily at a dose of 56 milligram per day (mg/d)
Percentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale.
End of Week 1
25.98 Percentage of Participants
Percentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale.
End of Week 2
51.97 Percentage of Participants
Percentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale.
End of Week 3
66.93 Percentage of Participants
Percentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale.
End of Week 7
78.74 Percentage of Participants
Percentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale.
End of Week 12
81.10 Percentage of Participants

SECONDARY outcome

Timeframe: Baseline and End of Week 12

Population: FAS for OROS-MPH Group included participants who took at least 1 study drug therapy and had at least 1 efficacy evaluation. FAS for normal group included participants who had baseline assessment scale evaluation and had at least 1 endpoint assessment scale evaluation. 'n'=participants who were evaluable at each specific time point for each arm.

This is a psychological test to observe the interference in which disparity between the meaning and color affects reading speed. A participant will be given 3 tasks of recognition: reading the printed colored ink (Color Test), reading color words in black ink (Word Test), and interference, reading color words printed in different colored ink (Word-Color Test). The test is scored on the number of correct answers. There are 100 items for each of the three categories and if they made it through the 100 words with time remaining, they would repeat the list. Median naming time in the Stroop color word naming test will be assessed. Stroop color word naming test 1 ,2 ,3 and 4 stand for gradually increased difficulty and each test has a corresponding baseline and endpoint.

Outcome measures

Outcome measures
Measure
OROS-MPH Group
n=128 Participants
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
n=40 Participants
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
OROS-MPH Group 54 mg
Participants with ADHD received OROS -MPH tablets orally daily at a dose of 56 milligram per day (mg/d)
Stroop Color Word Naming Test
Test 1: Baseline (n=128, 40)
20.561 Seconds
Standard Deviation 17.5433
6.213 Seconds
Standard Deviation 2.3174
Stroop Color Word Naming Test
Test 1: End of Week 12 (n=111, 40)
18.961 Seconds
Standard Deviation 5.4474
5.7 Seconds
Standard Deviation 1.8355
Stroop Color Word Naming Test
Test 2: Baseline (n=128, 40)
19.32 Seconds
Standard Deviation 14.8072
7.15 Seconds
Standard Deviation 2.6341
Stroop Color Word Naming Test
Test 2: End of Week 12 (n=111, 40)
18.281 Seconds
Standard Deviation 13.6981
6.675 Seconds
Standard Deviation 2.2886
Stroop Color Word Naming Test
Test 4: Baseline (n=128, 40)
22.868 Seconds
Standard Deviation 11.3502
11.763 Seconds
Standard Deviation 4.4202
Stroop Color Word Naming Test
Test 4: End of Week 12 (n=111, 40)
19.388 Seconds
Standard Deviation 9.8989
10.488 Seconds
Standard Deviation 4.2176
Stroop Color Word Naming Test
Test 3: Baseline (n=128, 40)
18.652 Seconds
Standard Deviation 14.5219
6.875 Seconds
Standard Deviation 2.6451
Stroop Color Word Naming Test
Test 3: End of Week 12 (n=111, 40)
16.946 Seconds
Standard Deviation 12.1586
6.513 Seconds
Standard Deviation 2.3898

SECONDARY outcome

Timeframe: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. "n" signifies participants who were evaluable at each time point for each specific arm.

WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. During number of trials administered or administered responses, participants were administered 128 cards and asked to sort the cards until all the 6 sorting categories was completed. Response number used to complete all 6 categories ranges from 50 to 128, lesser the better.

Outcome measures

Outcome measures
Measure
OROS-MPH Group
n=128 Participants
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
n=40 Participants
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
OROS-MPH Group 54 mg
Participants with ADHD received OROS -MPH tablets orally daily at a dose of 56 milligram per day (mg/d)
Wisconsin Card Sorting Test (WCST): Administered Responses (Ra) of Completed Examination
Baseline (n=128, 40)
125.1 Responses
Standard Deviation 8.74
120.8 Responses
Standard Deviation 5.53
Wisconsin Card Sorting Test (WCST): Administered Responses (Ra) of Completed Examination
End of Week 12 (n=111, 40)
116.4 Responses
Standard Deviation 17.68
117.1 Responses
Standard Deviation 17.37

SECONDARY outcome

Timeframe: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. "n" signifies participants who were evaluable at each time point for each specific arm.

WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. In completed categoriies, number of categories completed out of 6 sorting categories after the test was evaluated. Ranges from 0 to 6. The more the number of categories completed the better is the response.

Outcome measures

Outcome measures
Measure
OROS-MPH Group
n=128 Participants
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
n=40 Participants
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
OROS-MPH Group 54 mg
Participants with ADHD received OROS -MPH tablets orally daily at a dose of 56 milligram per day (mg/d)
WCST: Completed Categories (Cc)
End of Week 12 (n=111, 40)
4.1 Nunber of Categories Completed
Standard Deviation 1.54
4 Nunber of Categories Completed
Standard Deviation 1.34
WCST: Completed Categories (Cc)
Baseline (n=128, 40)
3.2 Nunber of Categories Completed
Standard Deviation 1.56
3.3 Nunber of Categories Completed
Standard Deviation 1.68

SECONDARY outcome

Timeframe: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. "n" signifies participants who were evaluable at each time point for each specific arm.

WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. The number of correct responses which meets all the requirements according to the response principles was evaluated. Ranges from 0-116, the more the better.

Outcome measures

Outcome measures
Measure
OROS-MPH Group
n=128 Participants
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
n=40 Participants
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
OROS-MPH Group 54 mg
Participants with ADHD received OROS -MPH tablets orally daily at a dose of 56 milligram per day (mg/d)
WCST: Correct Responses (Rc)
Baseline (n=128, 40)
72.9 number of correct responses
Standard Deviation 15.65
77.9 number of correct responses
Standard Deviation 12.27
WCST: Correct Responses (Rc)
End of Week 12 (n=111, 40)
80.3 number of correct responses
Standard Deviation 12.25
84.7 number of correct responses
Standard Deviation 12.3

SECONDARY outcome

Timeframe: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. "n" signifies participants who were evaluable at each time point for each specific arm.

WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Number of error responses which did not comply with the response principles was evaluated. Ranges from 0 to 128, the less the better.

Outcome measures

Outcome measures
Measure
OROS-MPH Group
n=128 Participants
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
n=40 Participants
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
OROS-MPH Group 54 mg
Participants with ADHD received OROS -MPH tablets orally daily at a dose of 56 milligram per day (mg/d)
WCST: Error Responses (Re)
Baseline (n=128, 40)
52.3 number of error responses
Standard Deviation 18.59
42.9 number of error responses
Standard Deviation 17.77
WCST: Error Responses (Re)
End of Week 12 (n= 111, 40)
36.1 number of error responses
Standard Deviation 16.93
32.3 number of error responses
Standard Deviation 15.11

SECONDARY outcome

Timeframe: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. "n" signifies participants who were evaluable at each time point for each specific arm.

WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Percentage of correct responses which meets all the requirements according to the response principles was evaluated. Ranges from 0 to 100 percent (%), the more the better.

Outcome measures

Outcome measures
Measure
OROS-MPH Group
n=128 Participants
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
n=40 Participants
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
OROS-MPH Group 54 mg
Participants with ADHD received OROS -MPH tablets orally daily at a dose of 56 milligram per day (mg/d)
WCST: Percentage of Correct Responses (Rc%)
Baseline (n=128, 40)
58.678 Percentage of correct responses
Standard Deviation 13.8072
65.52 Percentage of correct responses
Standard Deviation 12.6227
WCST: Percentage of Correct Responses (Rc%)
End of Week 12 (n=111, 40)
70.096 Percentage of correct responses
Standard Deviation 11.6311
73.34 Percentage of correct responses
Standard Deviation 10.5072

SECONDARY outcome

Timeframe: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. "n" signifies participants who were evaluable at each time point for each specific arm.

WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Number of responses needed to complete the first color classification was evaluated. Ranges from 9 to 128, the lesser the better.

Outcome measures

Outcome measures
Measure
OROS-MPH Group
n=128 Participants
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
n=40 Participants
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
OROS-MPH Group 54 mg
Participants with ADHD received OROS -MPH tablets orally daily at a dose of 56 milligram per day (mg/d)
WCST: First Response (Rf)
Baseline (n=128,40)
22.6 number of first responses
Standard Deviation 22.29
25.2 number of first responses
Standard Deviation 24.45
WCST: First Response (Rf)
End of Week 12 (n=111, 40)
23.4 number of first responses
Standard Deviation 19
26.5 number of first responses
Standard Deviation 22.77

SECONDARY outcome

Timeframe: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. "n" signifies participants who were evaluable at each time point for each specific arm.

WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Percentage of the responses completed with 3-10 continuous correct during the entire measuring process was evaluated. Ranges from 0 to 100%, the more the better.

Outcome measures

Outcome measures
Measure
OROS-MPH Group
n=128 Participants
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
n=40 Participants
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
OROS-MPH Group 54 mg
Participants with ADHD received OROS -MPH tablets orally daily at a dose of 56 milligram per day (mg/d)
WCST: Percentage of Conceptual Level Responses (Rf%)
Baseline (n=128, 40)
46.36 percentage of conceptual level responses
Standard Deviation 18.589
54.73 percentage of conceptual level responses
Standard Deviation 18.48
WCST: Percentage of Conceptual Level Responses (Rf%)
End of Week 12 (n=111, 40)
61.07 percentage of conceptual level responses
Standard Deviation 17.244
65 percentage of conceptual level responses
Standard Deviation 16.036

SECONDARY outcome

Timeframe: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. "n" signifies participants who were evaluable at each time point for each specific arm.

WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Number of perseverative responses were the responses which applied continuity principle for matching answers was evaluated. Ranges from 0 to 100, the less the better.

Outcome measures

Outcome measures
Measure
OROS-MPH Group
n=128 Participants
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
n=40 Participants
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
OROS-MPH Group 54 mg
Participants with ADHD received OROS -MPH tablets orally daily at a dose of 56 milligram per day (mg/d)
WCST: Perseverative Responses (Rp)
End of Week 12 (n=111, 40)
22 number of perseverative responses
Standard Deviation 16.21
18.6 number of perseverative responses
Standard Deviation 12.97
WCST: Perseverative Responses (Rp)
Baseline (n=128, 40)
33.7 number of perseverative responses
Standard Deviation 20.47
26.5 number of perseverative responses
Standard Deviation 14.09

SECONDARY outcome

Timeframe: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. "n" signifies participants who were evaluable at each time point for each specific arm.

WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Perseverative error responses are the number of responses which applied continuity principle for matching answers and also had the wrong answer was evaluated. Ranges from 0 to 128, the less the better.

Outcome measures

Outcome measures
Measure
OROS-MPH Group
n=128 Participants
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
n=40 Participants
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
OROS-MPH Group 54 mg
Participants with ADHD received OROS -MPH tablets orally daily at a dose of 56 milligram per day (mg/d)
WCST: Perseverative Error Responses (Rpe)
Baseline (n=128, 40)
28.7 number of perseverative error responses
Standard Deviation 15.24
23 number of perseverative error responses
Standard Deviation 11.03
WCST: Perseverative Error Responses (Rpe)
End of Week 12 (n=111, 40)
19.4 number of perseverative error responses
Standard Deviation 12.54
16.4 number of perseverative error responses
Standard Deviation 9.85

SECONDARY outcome

Timeframe: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. "n" signifies participants who were evaluable at each time point for each specific arm.

WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative (pvt) errors; nonperseverative errors; failure to maintain set; learning to learn. Percentage of persistent errors out of total number of responses was evaluated. Ranges from 0 to 100%, the less the better.

Outcome measures

Outcome measures
Measure
OROS-MPH Group
n=128 Participants
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
n=40 Participants
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
OROS-MPH Group 54 mg
Participants with ADHD received OROS -MPH tablets orally daily at a dose of 56 milligram per day (mg/d)
WCST: Percentage of Perseverative Error Responses (Rpe%)
Baseline (n=128, 40)
22.67 Percentage of pvt error responses
Standard Deviation 11.658
18.45 Percentage of pvt error responses
Standard Deviation 8.083
WCST: Percentage of Perseverative Error Responses (Rpe%)
End of Week 12 (n=111, 40)
16.07 Percentage of pvt error responses
Standard Deviation 9.188
13.59 Percentage of pvt error responses
Standard Deviation 7.167

SECONDARY outcome

Timeframe: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. "n" signifies participants who were evaluable at each time point for each specific arm.

WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Non perseverative error responses are the errors remaining after subtracting persistent errors from total errors. Ranges from 0 to 128 and was not linear (cannot be considered to be good or bad just judged by the number, analyzed with other factors case by case).

Outcome measures

Outcome measures
Measure
OROS-MPH Group
n=128 Participants
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
n=40 Participants
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
OROS-MPH Group 54 mg
Participants with ADHD received OROS -MPH tablets orally daily at a dose of 56 milligram per day (mg/d)
WCST: Non-Persistent Error Responses (nRpe)
Baseline (n=128, 40)
23.54 number of non-persistent error responses
Standard Deviation 11.606
19.98 number of non-persistent error responses
Standard Deviation 8.94
WCST: Non-Persistent Error Responses (nRpe)
End of Week 12 (n=111, 40)
16.75 number of non-persistent error responses
Standard Deviation 9.241
15.8 number of non-persistent error responses
Standard Deviation 7.737

SECONDARY outcome

Timeframe: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. "n" signifies participants who were evaluable at each time point for each specific arm.

WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. The frequency (number of times) of responses completed with 5 to 9 continuous correct was evaluated. Ranges from 0 to 26 and was not linear (cannot be considered to be good or bad just judged by the number, analyzed with other factors case by case).

Outcome measures

Outcome measures
Measure
OROS-MPH Group
n=128 Participants
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
n=40 Participants
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
OROS-MPH Group 54 mg
Participants with ADHD received OROS -MPH tablets orally daily at a dose of 56 milligram per day (mg/d)
WCST: Failure to Maintain Set (Fm)
Baseline (n=128, 40)
1.7 number of times
Standard Deviation 1.62
2.3 number of times
Standard Deviation 1.65
WCST: Failure to Maintain Set (Fm)
End of Week 12 (n=111, 40)
2 number of times
Standard Deviation 1.78
2.5 number of times
Standard Deviation 1.75

SECONDARY outcome

Timeframe: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. "n" signifies participants who were evaluable at each time point for each specific arm.

WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. "Learning to learn" indicator was a measure of decrement in the number of responses needed to achieve each successive category. The raw score ranged from 0 to 100. The high, negative value suggests the participants could not effectively learn the task presented by the WCST. Only calculated in those completed 3 or more categories and not linear (cannot be considered to be good or bad just judged by the number, analyzed with other factors case by case).

Outcome measures

Outcome measures
Measure
OROS-MPH Group
n=128 Participants
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
n=40 Participants
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
OROS-MPH Group 54 mg
Participants with ADHD received OROS -MPH tablets orally daily at a dose of 56 milligram per day (mg/d)
WCST: Learning to Learn (L-C)
Baseline (n=128, 40)
-2.49 number of responses
Standard Deviation 6.451
-2.37 number of responses
Standard Deviation 6.31
WCST: Learning to Learn (L-C)
End of Week 12 (n=111, 40)
-1.87 number of responses
Standard Deviation 3.85
-1.34 number of responses
Standard Deviation 4.391

SECONDARY outcome

Timeframe: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. "n" signifies participants who were evaluable at each time point for each specific arm.

The coding Test is a common test indicator for perceptual speed. The test presents a series of corresponding relationship between graphics and symbols to the participant, and then participants will be required to fill out the appropriate symbol following single symbol in the test part. The test is limited within 150 seconds and evaluated the number of symbols been replaced correctly by the participants.

Outcome measures

Outcome measures
Measure
OROS-MPH Group
n=128 Participants
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
n=40 Participants
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
OROS-MPH Group 54 mg
Participants with ADHD received OROS -MPH tablets orally daily at a dose of 56 milligram per day (mg/d)
Coding Test
Baseline (n=128, 40)
63.4 Number of symbols correctly replaced
Standard Deviation 40.14
77.4 Number of symbols correctly replaced
Standard Deviation 44.83
Coding Test
End of Week 12 (n=111, 40)
73.2 Number of symbols correctly replaced
Standard Deviation 41.41
83.1 Number of symbols correctly replaced
Standard Deviation 44.19

SECONDARY outcome

Timeframe: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. "n" signifies participants who were evaluable at each time point for each specific arm.

Mathematics and language scores will be obtained from their corresponding examinations at school. Scores ranges from 0-100 respectively. Mathematics and language would be summarized separately.

Outcome measures

Outcome measures
Measure
OROS-MPH Group
n=128 Participants
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
n=40 Participants
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
OROS-MPH Group 54 mg
Participants with ADHD received OROS -MPH tablets orally daily at a dose of 56 milligram per day (mg/d)
Academic Achievement
Chinese Achievement: Basline (n=128, 40)
77.35 scores on a scale
Standard Deviation 13.791
94.21 scores on a scale
Standard Deviation 4.301
Academic Achievement
Chinese Achievement: End of Week 12(n=111, 40)
83.94 scores on a scale
Standard Deviation 10.737
94.56 scores on a scale
Standard Deviation 4.396
Academic Achievement
Mathematical Achievement (MA):Baseline (n=128, 40)
78.86 scores on a scale
Standard Deviation 15.407
96.23 scores on a scale
Standard Deviation 3.641
Academic Achievement
MA: End of Week 12 (n=111, 40)
86.05 scores on a scale
Standard Deviation 11.579
96.13 scores on a scale
Standard Deviation 3.625

SECONDARY outcome

Timeframe: End of Week 1, 2, 3, 7 and 12

Population: FAS population for OROS-MPH Group included all participants who received at least one study drug therapy and had at least one efficacy evaluation. Data for Normal group was not analyzed for IOWA Conners scale since as per the planned analysis normal participants were only analyzed for the memory effect in cognitive function test

CGI is an overall rating scale. Clinical Global Impression (Improvement of Diseases) is divided into seven grades: 1=very significant improvement, 24=significant improvement or advanced, 3=improvement or slightly advanced, 4=no change, 5=slight aggravation, 6=significant aggravation, and 7=very significant aggravation or seriously aggravated. Number of participants in each category of grade were assessed.

Outcome measures

Outcome measures
Measure
OROS-MPH Group
n=128 Participants
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
OROS-MPH Group 54 mg
Participants with ADHD received OROS -MPH tablets orally daily at a dose of 56 milligram per day (mg/d)
Number of Participants With Clinical Global Impression - CGI Scale Score
Slightly Advanced: End of Week 1
33 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
Advanced: End of Week 12
46 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
Significantly Advanced: End of Week 1
20 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
Significantly Advanced: End of Week 2
28 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
Significantly Advanced: End of Week 3
29 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
Significantly Advanced: End of Week 7
35 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
Significantly Advanced: End of Week 12
36 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
Advanced: End of Week 1
59 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
Advanced: End of Week 2
53 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
Advanced: End of Week 3
44 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
Advanced: End of Week 7
41 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
Slightly Advanced: End of Week 2
28 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
Slightly Advanced: End of Week 3
33 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
Slightly Advanced: End of Week 7
28 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
Slightly Advanced: End of Week 12
25 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
No Change: End of Week 1
15 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
No Change: End of Week 2
10 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
No Change: End of Week 3
11 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
No Change: End of Week 7
7 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
No Change: End of Week 12
3 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
Slightly Aggravated: End of Week 1
0 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
Slightly Aggravated: End of Week 2
2 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
Slightly Aggravated: End of Week 3
0 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
Slightly Aggravated: End of Week 7
3 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
Slightly Aggravated: End of Week 12
1 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
Aggravated: End of Week 1
0 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
Aggravated: End of Week 2
0 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
Aggravated: End of Week 3
0 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
Aggravated: End of Week 7
0 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
Aggravated: End of Week 12
0 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
Seriously Aggravated: End of Week 1
0 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
Seriously Aggravated: End of Week 2
0 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
Seriously Aggravated: End of Week 3
0 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
Seriously Aggravated: End of Week 7
0 Participants
Number of Participants With Clinical Global Impression - CGI Scale Score
Seriously Aggravated: End of Week 12
0 Participants

SECONDARY outcome

Timeframe: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included all participants who received at least one study drug therapy and had at least one efficacy evaluation. Here "N" signifies participants who were evaluable for this outcome measure.

IOWA conners behavior rating scale score in different dosage groups will be accessed to evaluate relationship between therapeutic effect and dosage. IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening.

Outcome measures

Outcome measures
Measure
OROS-MPH Group
n=86 Participants
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
n=30 Participants
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
OROS-MPH Group 54 mg
n=1 Participants
Participants with ADHD received OROS -MPH tablets orally daily at a dose of 56 milligram per day (mg/d)
Change From Baseline in I/O Score of IOWA Conners Behavior Rating Scale at Week 12
Baseline
10 Scores on a scale
Standard Deviation 2.42
10.3 Scores on a scale
Standard Deviation 2.39
7 Scores on a scale
Standard Deviation 0
Change From Baseline in I/O Score of IOWA Conners Behavior Rating Scale at Week 12
Change at End of Week 12
-6.8 Scores on a scale
Standard Deviation 2.82
-5.8 Scores on a scale
Standard Deviation 3.32
-4 Scores on a scale
Standard Deviation 0

SECONDARY outcome

Timeframe: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included all participants who received at least one study drug therapy and had at least one efficacy evaluation. Here "N" signifies participants who were evaluable for this outcome measure.

The digit span test total score will be accessed in different dosage groups to evaluate the relationship between therapeutic effect and dosage. The digit span test is mainly used to measure the ability of short-term memory and attention. The participant will be given a string of digits and asked to repeat them forward, and then a second string of digits to repeat backward. The score is the number of correct responses, where the digits were repeated correctly. One point will be given for each correctly repeated string of digits. The maximum subscore in the Digits Forward is16, and the maximum subscore in the Digits Backward is 14, for a total score of 30. A higher score was indicative of better recall and attention.

Outcome measures

Outcome measures
Measure
OROS-MPH Group
n=86 Participants
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
n=30 Participants
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
OROS-MPH Group 54 mg
n=1 Participants
Participants with ADHD received OROS -MPH tablets orally daily at a dose of 56 milligram per day (mg/d)
Change From Baseline in Total Scores of Digit Span Test at Week 12
Baseline
11.7 Scores on a scale
Standard Deviation 2.4
11.3 Scores on a scale
Standard Deviation 1.95
15 Scores on a scale
Standard Deviation 0
Change From Baseline in Total Scores of Digit Span Test at Week 12
Change at End of Week 12
1.2 Scores on a scale
Standard Deviation 1.54
0.8 Scores on a scale
Standard Deviation 1.56
0 Scores on a scale
Standard Deviation 0

SECONDARY outcome

Timeframe: Baseline and End of Week 12

Population: FAS population for OROS-MPH Group included all participants who received at least one study drug therapy and had at least one efficacy evaluation. Here "N" signifies participants who were evaluable for this outcome measure and "n" signifies participants who were evaluable at each time point for each specific arm.

Completion time of stroop color-word test in different dosage groups will be accessed to evaluate the relationship between therapeutic effect and dosage. This is a psychological test to observe the interference in which disparity between the meaning and color affects reading speed. A participant will be given 3 tasks of recognition: reading the printed colored ink (Color Test), reading color words in black ink (Word Test), and interference, reading color words printed in different colored ink (Word-Color Test). The test will be scored on the number of correct answers. There are 100 items for each of the three categories and if they made it through the 100 words with time remaining, they would repeat the list. Median time of the naming time in the Stroop color word naming test will be accessed. Stroop color word naming test 1 ,2 ,3 and 4 stand for gradually increased difficulty and each test has a corresponding baseline and endpoint.

Outcome measures

Outcome measures
Measure
OROS-MPH Group
n=86 Participants
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
n=30 Participants
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
OROS-MPH Group 54 mg
n=1 Participants
Participants with ADHD received OROS -MPH tablets orally daily at a dose of 56 milligram per day (mg/d)
Change From Baseline in Completion Time of Stroop Color-word Test at Week 12
Test 4: Baseline (n=86, 30, 1)
23.61 Seconds
Standard Deviation 12.135
22.154 Seconds
Standard Deviation 9.2451
15 Seconds
Standard Deviation 0
Change From Baseline in Completion Time of Stroop Color-word Test at Week 12
Test 1: Baseline (n=86, 30, 1)
22.229 Seconds
Standard Deviation 18.7304
17.7 Seconds
Standard Deviation 13.654
5 Seconds
Standard Deviation 0
Change From Baseline in Completion Time of Stroop Color-word Test at Week 12
Test 1: Change at End of Week 12 (n=82, 27, 1)
-3.318 Seconds
Standard Deviation 5.6413
-1 Seconds
Standard Deviation 4.308
0 Seconds
Standard Deviation 0
Change From Baseline in Completion Time of Stroop Color-word Test at Week 12
Test 2: Baseline (n=86, 30, 1)
20.538 Seconds
Standard Deviation 15.3567
17.29 Seconds
Standard Deviation 11.7025
9 Seconds
Standard Deviation 0
Change From Baseline in Completion Time of Stroop Color-word Test at Week 12
Test 2: Change at End of Week 12 (n=82, 27, 1)
-2.164 Seconds
Standard Deviation 5.2669
-1.233 Seconds
Standard Deviation 3.9809
0 Seconds
Standard Deviation 0
Change From Baseline in Completion Time of Stroop Color-word Test at Week 12
Test 3: Baseline (n=86, 30, 1)
19.515 Seconds
Standard Deviation 14.6203
17.473 Seconds
Standard Deviation 14.2673
7 Seconds
Standard Deviation 0
Change From Baseline in Completion Time of Stroop Color-word Test at Week 12
Test 3: Change at End of Week 12 (n=82, 27, 1)
-2.336 Seconds
Standard Deviation 5.3987
-2.996 Seconds
Standard Deviation 6.6313
3 Seconds
Standard Deviation 0
Change From Baseline in Completion Time of Stroop Color-word Test at Week 12
Test 4: Change at End of Week 12 (n=82, 27, 1)
-4.374 Seconds
Standard Deviation 7.5921
-3.974 Seconds
Standard Deviation 6.0143
1 Seconds
Standard Deviation 0

SECONDARY outcome

Timeframe: Week 12

Population: FAS population for OROS-MPH Group included all participants who received at least one study drug therapy and had at least one efficacy evaluation. Here "N" signifies participants who were evaluable for this outcome measure.

Remission rate in different dosage groups will be accessed to evaluate the relationship between therapeutic effect and dosage. Remission rate is the percentage of participants with total score of IO sub-scale less than or equal to 5 in IOWA Conners measurement scale.

Outcome measures

Outcome measures
Measure
OROS-MPH Group
n=86 Participants
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
n=30 Participants
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
OROS-MPH Group 54 mg
n=1 Participants
Participants with ADHD received OROS -MPH tablets orally daily at a dose of 56 milligram per day (mg/d)
Percentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale at Week 12
85.37 Percentage of participants
74.07 Percentage of participants
100.00 Percentage of participants

SECONDARY outcome

Timeframe: End of Week 12

Population: FAS population for OROS-MPH Group. Here "N" signifies participants who were evaluable for this outcome measure. Data for Normal group was not analyzed for IOWA Conners scale since as per the planned analysis normal participants were only analyzed for the memory effect in cognitive function test.

Number of Participants who are Compliant with Treatment will be accessed. Less than 80 percent and more than 120 percent compliance signifies bad compliance, 80 to 120 percent compliance signifies good compliance . The compliance was calculated by the percentage of dose (actual dose multiplied by 100/theoretical dose).The theoretical dose means the dose prescribed by the Investigator.

Outcome measures

Outcome measures
Measure
OROS-MPH Group
n=127 Participants
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Normal Group
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
OROS-MPH Group 54 mg
Participants with ADHD received OROS -MPH tablets orally daily at a dose of 56 milligram per day (mg/d)
Number of Participants Compliant With Treatment
Less than 80 percent
17 participants
Number of Participants Compliant With Treatment
Between 80 to 120 percent
110 participants
Number of Participants Compliant With Treatment
More than 120 percent
0 participants

Adverse Events

OROS-MPH Group

Serious events: 0 serious events
Other events: 27 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
OROS-MPH Group
n=149 participants at risk
Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
Metabolism and nutrition disorders
Loss of Appetite
12.8%
19/149
Safety Set for OROS-MPH Group included all participants who received at least one study drug therapy and at least one safety evaluation. Adverse events was not evaluated for normal group as participants did not receive any study drug in this group. Participants were only assessed for changes in the cognitive functions.
Ear and labyrinth disorders
Tinnitus
0.67%
1/149
Safety Set for OROS-MPH Group included all participants who received at least one study drug therapy and at least one safety evaluation. Adverse events was not evaluated for normal group as participants did not receive any study drug in this group. Participants were only assessed for changes in the cognitive functions.
Infections and infestations
Tonsillitis
0.67%
1/149
Safety Set for OROS-MPH Group included all participants who received at least one study drug therapy and at least one safety evaluation. Adverse events was not evaluated for normal group as participants did not receive any study drug in this group. Participants were only assessed for changes in the cognitive functions.
Investigations
Abnormal Heart Rate
0.67%
1/149
Safety Set for OROS-MPH Group included all participants who received at least one study drug therapy and at least one safety evaluation. Adverse events was not evaluated for normal group as participants did not receive any study drug in this group. Participants were only assessed for changes in the cognitive functions.
Investigations
Decreased Blood Pressure
1.3%
2/149
Safety Set for OROS-MPH Group included all participants who received at least one study drug therapy and at least one safety evaluation. Adverse events was not evaluated for normal group as participants did not receive any study drug in this group. Participants were only assessed for changes in the cognitive functions.
Nervous system disorders
Low sleep quality
2.0%
3/149
Safety Set for OROS-MPH Group included all participants who received at least one study drug therapy and at least one safety evaluation. Adverse events was not evaluated for normal group as participants did not receive any study drug in this group. Participants were only assessed for changes in the cognitive functions.
Nervous system disorders
Headache
1.3%
2/149
Safety Set for OROS-MPH Group included all participants who received at least one study drug therapy and at least one safety evaluation. Adverse events was not evaluated for normal group as participants did not receive any study drug in this group. Participants were only assessed for changes in the cognitive functions.
Nervous system disorders
Dizziness
1.3%
2/149
Safety Set for OROS-MPH Group included all participants who received at least one study drug therapy and at least one safety evaluation. Adverse events was not evaluated for normal group as participants did not receive any study drug in this group. Participants were only assessed for changes in the cognitive functions.
Respiratory, thoracic and mediastinal disorders
Nasopharyngitis
0.67%
1/149
Safety Set for OROS-MPH Group included all participants who received at least one study drug therapy and at least one safety evaluation. Adverse events was not evaluated for normal group as participants did not receive any study drug in this group. Participants were only assessed for changes in the cognitive functions.
Respiratory, thoracic and mediastinal disorders
Epistaxis
0.67%
1/149
Safety Set for OROS-MPH Group included all participants who received at least one study drug therapy and at least one safety evaluation. Adverse events was not evaluated for normal group as participants did not receive any study drug in this group. Participants were only assessed for changes in the cognitive functions.
Respiratory, thoracic and mediastinal disorders
Cough
0.67%
1/149
Safety Set for OROS-MPH Group included all participants who received at least one study drug therapy and at least one safety evaluation. Adverse events was not evaluated for normal group as participants did not receive any study drug in this group. Participants were only assessed for changes in the cognitive functions.
Respiratory, thoracic and mediastinal disorders
Mouth and Pharynx Pain
0.67%
1/149
Safety Set for OROS-MPH Group included all participants who received at least one study drug therapy and at least one safety evaluation. Adverse events was not evaluated for normal group as participants did not receive any study drug in this group. Participants were only assessed for changes in the cognitive functions.
Respiratory, thoracic and mediastinal disorders
Upper Respiratory Tract Infection
2.0%
3/149
Safety Set for OROS-MPH Group included all participants who received at least one study drug therapy and at least one safety evaluation. Adverse events was not evaluated for normal group as participants did not receive any study drug in this group. Participants were only assessed for changes in the cognitive functions.
Psychiatric disorders
Difficulty in falling asleep
0.67%
1/149
Safety Set for OROS-MPH Group included all participants who received at least one study drug therapy and at least one safety evaluation. Adverse events was not evaluated for normal group as participants did not receive any study drug in this group. Participants were only assessed for changes in the cognitive functions.
Psychiatric disorders
Insomnia
2.0%
3/149
Safety Set for OROS-MPH Group included all participants who received at least one study drug therapy and at least one safety evaluation. Adverse events was not evaluated for normal group as participants did not receive any study drug in this group. Participants were only assessed for changes in the cognitive functions.
Psychiatric disorders
Irritability
0.67%
1/149
Safety Set for OROS-MPH Group included all participants who received at least one study drug therapy and at least one safety evaluation. Adverse events was not evaluated for normal group as participants did not receive any study drug in this group. Participants were only assessed for changes in the cognitive functions.
General disorders
Fever
0.67%
1/149
Safety Set for OROS-MPH Group included all participants who received at least one study drug therapy and at least one safety evaluation. Adverse events was not evaluated for normal group as participants did not receive any study drug in this group. Participants were only assessed for changes in the cognitive functions.
Gastrointestinal disorders
Nausea
1.3%
2/149
Safety Set for OROS-MPH Group included all participants who received at least one study drug therapy and at least one safety evaluation. Adverse events was not evaluated for normal group as participants did not receive any study drug in this group. Participants were only assessed for changes in the cognitive functions.
Nervous system disorders
Difficulty in falling asleep
0.67%
1/149
Safety Set for OROS-MPH Group included all participants who received at least one study drug therapy and at least one safety evaluation. Adverse events was not evaluated for normal group as participants did not receive any study drug in this group. Participants were only assessed for changes in the cognitive functions.

Additional Information

Director - CNS & Pain, CDMA, China R&D and SA

Xi'an Janssen Pharmaceutical Ltd.

Phone: +86 10 5821-8307

Results disclosure agreements

  • Principal investigator is a sponsor employee The only disclosure restriction on the PI is a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days .In the event that issues arise regarding scientific integrity, the sponsor will review these issues with the investigator.
  • Publication restrictions are in place

Restriction type: OTHER